Pre Diagnostics

Pre Diagnostics is a Norwegian diagnostic company specializing in the development of blood-based tests for the early detection of Alzheimer's disease. The company's unique approach focuses on the role of monocytes in clearing amyloid-beta from the brain, measuring intracellular biomarkers rather than just plasma levels. Their lead product, PreAD, is designed to identify individuals in the early stages of neurodegeneration, providing a cost-effective and minimally invasive alternative to traditional PET scans and lumbar punctures. By enabling earlier diagnosis, Pre Diagnostics aims to improve patient outcomes and support the development of new disease-modifying therapies. The company leverages a proprietary platform that assesses the functional capacity of the immune system to handle disease-related proteins.